Innoviva, Inc. (INVA) vs Stoke Therapeutics, Inc. (STOK)

A side-by-side comparison of Innoviva, Inc. and Stoke Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Innoviva, Inc. logo
INVA
Innoviva, Inc.
$1.54B
$20.91HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Stoke Therapeutics, Inc. logo
STOK
Stoke Therapeutics, Inc.
$1.53B
$23.77HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT

Total return — INVA vs STOK

growth of $100 · dividends reinvested · last 7y
INVA +46.6% (+5.6%/yr)STOK -1.0% (-0.1%/yr)INVA compounded faster over this window
0100200Start $100202120232025$147$99
INVA STOK

INVA vs STOK: by the numbers

  • •INVA is the larger company ($1.54B vs $1.53B market cap).
  • •INVA is profitable (80.56% net margin) while STOK runs a net loss (-753.60%).

Metrics side by side

Valuation

MetricINVASTOK
P/E ratio5.10N/A
Forward P/E8.64N/A
PEG ratio0.49N/A
P/S ratio3.4855.61
P/B ratio1.254.44
EV / EBITDA4.92N/A
FCF yield12.20%N/A

Profitability

MetricINVASTOK
Gross margin73.09%100.00%
Operating margin36.66%-11.16%
Net margin80.56%-753.60%
ROE28.97%-60.17%
ROIC8.36%-63.12%

Growth (annualized)

MetricINVASTOK
Revenue CAGR (5Y)3.94%N/A
EPS CAGR (5Y)12.71%N/A
FCF CAGR (5Y)-10.54%N/A
Total return CAGR (5Y)4.52%-0.24%

Frequently asked

Is INVA or STOK more profitable?
INVA runs the higher net margin — INVA at 80.56% versus STOK at -753.60%.
How have INVA and STOK total returns compared?
Over the past 5 years, INVA delivered 4.52% and STOK delivered -0.24% annualized total return. Past performance doesn't predict future results.

Go deeper

Full INVA analysisFull STOK analysisInteractive comparison tool

Dig into the metrics

Innoviva P/E ratioInnoviva ROEStoke Therapeutics ROEInnoviva operating marginStoke Therapeutics operating marginInnoviva revenue growthStoke Therapeutics revenue growthInnoviva free cash flowStoke Therapeutics free cash flow

Innoviva & Stoke Therapeutics appear in these rankings

Highest ROE StocksHighest Operating Margin StocksHighest FCF Yield StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.